AstraZeneca To Pay Merck $647M For Drug Stake
AstraZeneca PLC will pay $647 million to exercise its option for Merck & Co. Inc.'s share in the U.K.-based pharmaceutical company's nonproton pump inhibitor drugs used mainly to treat high blood...To view the full article, register now.
Already a subscriber? Click here to view full article